PSTV PLUS THERAPEUTICS, INC. Insider Trading

CFO Andrew MacIntyre buys 20,000 PSTV shares at $0.51; stock now -65.3% from 52-week high, but his 2 prior PSTV buys had 90d returns of +2459.1% and +2557.5%.

CFO Andrew MacIntyre purchased 20,000 shares of PLUS THERAPEUTICS at $0.51, increasing his holdings by 41.5% to 68.1K shares. The timing is notable: his prior two purchases at this ticker (2024-09-10 and 2024-05-08) both generated substantial 90-day returns (+2459.1% and +2557.5% respectively), and both were well-timed buys. His cross-ticker track record shows 2 prior buys with average 90d return of +2209.1% and a 100% win rate. However, the current context is concerning: PSTV stock has fallen -65.3% from its 52-week high of $39.25 and -38.8% in the past 30 days alone. The company reported quarterly revenue of $1.4M against a net loss of $4.4M, and while annual revenue grew 18.5%, the firm remains unprofitable. The purchase price of $0.51 represents a steep valuation compression from the prior highs, yet the execution against an already-weak price trajectory and unprofitable fundamentals differs materially from his prior two well-timed entries into this stock.

Director Robert P Lenk bought 110,000 shares of PSTV at $0.49 (2025-08-22); prior 5 trades at this ticker show 100% 90-day success rate.

Director Robert P Lenk purchased 110,000 shares at $0.49, increasing his holdings from 29.3K to 139.3K shares (+375.1% increase). This represents a substantial accumulation at a price well below the 52-week high of $46.25. His prior trade history at this specific ticker is notably consistent: across 5 prior purchases at PSTV, all 5 trades showed positive 90-day returns (range +1860.8% to +3676.2%), establishing a 100% timing success rate at this ticker. His cross-ticker open-market track record similarly shows 9 prior buys with an average 90-day return of +2831.0% and a 100% win rate. The current stock price of $12.13 is down 8.4% over 30 days and -73.8% from its 52-week high, creating a substantially depressed entry point relative to recent price action. However, the company reported a latest quarterly revenue of $1,390,000.00 with positive net income of $5,151,000.00, though it was unprofitable over its most recent full fiscal year, presenting a mixed fundamental picture.

Director Hawkins buys 4,000 PSTV shares at $1.50; 4 other insiders bought within 14 days as cluster activity.

Richard J Hawkins, a director of PLUS THERAPEUTICS, purchased 4,000 shares at $1.50 on 2024-09-13, increasing his holdings by 35.8% to 15,188 shares post-transaction. This buy occurs within a cluster pattern: 4 other insiders also acquired shares within the past 14 days, suggesting coordinated or independently-motivated director-level confidence. At the transaction price of $1.50, the stock was significantly depressed—currently trading at $39.75, a 2,550% appreciation from the buy price. Notably, Hawkins' prior trade at PSTV on 2024-05-08 (a buy at $1.50 equivalent value) achieved a 90-day return of +1860.8%, while his cross-ticker track record across 2 prior buys shows a 100% win rate with an average 90-day return of +1860.8%, indicating a strong historical pattern of well-timed accumulation. However, the company remains unprofitable with a net loss of $-2.9M in the latest quarter, though annual revenue growth stands at +36.5%, creating a contrasting fundamental picture of operational losses alongside revenue expansion.

Director Hawkins buys 6,285 shares of PSTV at $1.35; holdings surge to 11,188 shares; 4 other insiders bought in past 14 days

Hawkins Richard J (Director) purchased 6,285 shares at $1.35, increasing his position from 4,903 to 11,188 shares, a 128.2% increase. This transaction is part of a cluster pattern in which 4 other insiders also bought within the past 14 days, suggesting coordinated or simultaneous board interest. His cross-ticker track record shows strong past performance (2 prior buys with 100.00% 90-day win rate), and his prior PSTV purchase on 2024-05-08 delivered +1860.8% over 90 days. However, the current fundamental picture is mixed: PLUS THERAPEUTICS generated only $703.0K in quarterly revenue, remains unprofitable with $-2.9M net income, and the stock is currently -42.6% from its 52-week high despite +11.0% 30-day momentum. The multi-insider buying activity and insider's favorable historical timing merit investor attention to the company's operational trajectory.

Director Petersen buys 12,500 PSTV shares at $1.35; prior same-ticker buys showed 90d returns of +2779.9% and +3012.0%.

Petersen Greg, a director, purchased 12,500 shares of PLUS THERAPEUTICS at $1.35 on 2024-09-11, increasing his holdings by 34.3% to 48.9K shares. His prior two buys at this same ticker on 2024-05-08 and 2023-09-11 generated 90-day returns of +2779.9% and +3012.0% respectively, establishing a pattern of exceptionally well-timed entry points at PSTV. The current filing occurs alongside a cluster of 4 other insiders buying within the past 14 days, suggesting coordinated confidence at the company level. While the stock is currently -43.7% from its 52-week high and the company reports unprofitability (net income $-2.9M) against quarterly revenue of $703.0K, the director's historical execution at this specific ticker—achieving two consecutive large 90-day gains—warrants attention to whether this third buy mirrors the same market conditions that preceded those prior rallies.

Director Clowes Howard bought 5,000 PSTV shares at $1.34 on 2024-09-11; 4 other insiders also bought within 14 days amid unprofitable operations.

Clowes Howard, a Director, purchased 5,000 shares at $1.34, expanding his holdings to 26,497 shares—a 23.3% increase. This transaction occurs as part of a cluster pattern: 4 other insiders also bought PSTV stock within the past 14 days, suggesting coordinated or synchronized confidence in the stock despite material headwinds. The company is currently unprofitable with a net income of $-2.9M in its latest quarter, though it posted annual revenue growth of +36.5% year-over-year. Notably, Howard's prior 4 purchases at PSTV all demonstrated positive 90-day returns (ranging from +1,616.8% to +3,633.2%), and his cross-ticker track record across 4 prior buys shows an average 90-day return of +2,192.4% with a 100% win rate. The convergence of multiple insider purchases amid unprofitable fundamentals but strong revenue trajectory and Howard's consistent timing success at this ticker warrants investor attention to the company's operational turnaround narrative.

CFO Andrew MacIntyre buys 4,098 shares of PSTV at $1.27; stock down 54.6% from 52-week high; cluster pattern with 3 other insiders buying within 14 days.

Andrew MacIntyre, Chief Financial Officer, purchased 4,098 shares at $1.27, increasing his holdings from 5,717 to 9,815 shares (a 71.7% increase in his position). This purchase occurs while PSTV is trading 54.6% below its 52-week high of $74.25 and has declined 36.6% over the past 90 days. Notably, a cluster pattern shows 3 other insiders also bought within the past 14 days, suggesting broader internal conviction at current price levels. MacIntyre's prior PSTV purchase on 2024-05-08 was well-timed at the 90-day mark with a 1860.8% 90-day return, establishing a track record of favorable timing on this specific stock. Against this backdrop, the company remains unprofitable (net income of $-2.9M in the latest quarter, negative full-year net income) despite revenue growth of 36.5% year-over-year, creating a valuation context where insider accumulation may warrant investor scrutiny of underlying business momentum.

CEO Marc Hedrick bought 8,000 shares of PSTV at $1.23; stock now $33.75 (down 54.6% from 52-week high), 3 other insiders also bought in past 14 days

Chief Executive Officer Marc Hedrick purchased 8,000 shares at $1.23 on 2024-09-10, increasing his holdings by 64.4% to 20.4K shares. This represents his second open-market purchase of PSTV; his prior buy on 2024-05-08 posted a 90d return of +1860.8%. The current transaction occurred as the stock is trading 54.6% below its 52-week high and down 36.6% over 90 days. A cluster pattern is present, with 3 other insiders also purchasing within the past 14 days. The company reported latest-quarter revenue of $703.0K with a net loss of $-2.9M, though annual revenue growth stands at 36.5% year-over-year. The concentration of insider buying despite recent price weakness and ongoing unprofitability merits investor attention to the company's underlying fundamentals and management's forward outlook.